News | September 07, 2008

Inverness Medical Launches Portable Blood Testing to Warn Patients of Potential Blood Clots

September 8. 2008 - Inverness Medical Physician Diagnostics Group, a division of Inverness Medical Innovations, today launched the INRatio2 PT/INR Monitoring System, a portable device that measures blood-clotting time, also known as prothrombin time, using one drop of blood from a patient’s finger.

The INRatio2 is used by healthcare professionals and their patients in the management of warfarin, a blood-thinning drug, to monitor the effectiveness of the drug and warn of potential blood clots and other bleeding risks. Warfarin, also sold under the brand name Coumadin, is prescribed to patients to prevent blood clots, heart attacks, deep vein thrombosis, and stroke. Warfarin is the second most common cause of emergency room visits related to adverse drug events, trailing only insulin. The FDA estimates 2 million Americans start taking warfarin every year, and many will take the drug for the rest of their lives. Due to the serious bleeding risks associated with warfarin, the FDA has labeled it with a “black box” warning, informing consumers of the major and potentially fatal risks, and indicating that patients should have their PT/INR monitored regularly.

The INRatio2 PT/INR Monitoring System has been cleared by the FDA for warfarin patients to test themselves at home, offering patients quick access to their PT/INR results. The test results are then transmitted to their treating physician by telephone or the Internet. The results provide important data that helps physicians make informed warfarin dosing adjustments to ensure that patients stay within their recommended therapeutic range. Warfarin can be difficult to manage due to the wide variance in each patient’s response to the drug, in addition to factors such as diet, age, illness, and interaction with other drugs, the company said.

The INRatio2 offers many patient-friendly features, including a one-minute test time, easy single button interface, and 200-test battery life. Its simple fingerstick test procedure, light weight (9.3 oz), and individually-sealed test strip packaging enables patients to easily test themselves at home or when traveling.

For more information: www.hemosense.com

Related Content

Quantum Genomics Enrolls First Patient in QUORUM Phase IIb Study of Firibastat
News | Pharmaceuticals | June 14, 2019
Quantum Genomics announced the enrollment of the first patient in its QUORUM Phase IIb study of its lead clinical...
FDA Grants Priority Review for Vascepa sNDA
News | Pharmaceuticals | May 29, 2019
Amarin Corp. plc announced that its supplemental new drug application (sNDA) for Vascepa (icosapent ethyl) capsules has...
Vascepa Markedly Reduces First, Repeat and Total Cardiovascular Events
News | Pharmaceuticals | March 29, 2019
Taking a high dose of icosapent ethyl significantly reduces the occurrence of first, subsequent and total ischemic...
Bempedoic Acid Combination Tablet Significantly Lowers LDL-Cholesterol

Image courtesy of Esperion

News | Pharmaceuticals | March 25, 2019
Phase 3 results from Study 2, also known as CLEAR WISDOM, of bempedoic acid were recently presented at the American...
Aurobindo Pharma Adds to Nationwide Valsartan Blood Pressure Medication Recall
News | Pharmaceuticals | January 10, 2019
January 10, 2019 — Aurobindo Pharma USA Inc.
Mylan Expands Nationwide Recall of Valsartan Blood Pressure Medication
News | Pharmaceuticals | December 11, 2018
December 11, 2018 — Mylan Pharmaceuticals is expanding its consumer-level voluntary nationwide recall to include all
Farxiga Reduces Heart Failure Hospitalization, Cardiovascular Death for Type 2 Diabetes
News | Pharmaceuticals | November 15, 2018
AstraZeneca announced positive full results from the DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) for...
Vascepa and Statins Significantly Reduce Cardiovascular Events in the REDUCE-IT trial. #AHA #AHA18 #AHA2018
News | Pharmaceuticals | November 13, 2018
A study in the current edition of the New England Journal of Medicine shows that a particular treatment significantly...
Evolocumab Benefits High-Risk Patients With Established Cardiovascular and Chronic Kidney Disease
News | Pharmaceuticals | October 31, 2018
Amgen announced a new Repatha cardiovascular outcomes study (FOURIER) analysis evaluating the effects of Repatha (...
Overlay Init